» Articles » PMID: 16490890

Corticosteroid Use in the Intensive Care Unit: at What Cost?

Overview
Journal Arch Surg
Specialty General Surgery
Date 2006 Feb 24
PMID 16490890
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Hypothesis: Corticosteroid use has a significant effect on morbidity and mortality in the intensive care unit (ICU).

Design: Case-control study.

Setting: Burn-trauma ICU in a level 1 trauma center.

Patients: All patients who received corticosteroids while in the ICU from January 1, 2002, to December 31, 2003 (n = 100), matched by age and Injury Severity Score with a control group (n = 100).

Interventions: None.

Main Outcome Measures: We considered the following 7 outcomes: pneumonia, bloodstream infection, urinary tract infection, other infections, ICU length of stay (LOS), ventilator LOS, and mortality.

Results: Cases and controls had similar APACHE II (Acute Physiology and Chronic Health Evaluation II) scores and medical history. In univariate analysis, the corticosteroid group had a significant increase in pneumonia (26% vs 12%; P<.01), bloodstream infection (19% vs 7%; P<.01), and urinary tract infection (17% vs 8%; P<.05). In multivariate models, corticosteroid use was associated with an increased rate of pneumonia (odds ratio [OR], 2.64; 95% confidence interval [CI], 1.21-5.75) and bloodstream infection (OR, 3.25; 95% CI, 1.26-8.37). There was a trend toward increased urinary tract infection (OR, 2.31; 95% CI, 0.94-5.69), other infections (OR, 2.57; 95% CI, 0.87-7.67), and mortality (OR, 1.89; 95% CI, 0.81-4.40). Patients in the ICU who received corticosteroids had a longer ICU LOS by 7 days (P<.01) and longer ventilator LOS by 5 days (P<.01).

Conclusions: Corticosteroid use is associated with increased rate of infection, increased ICU and ventilator LOS, and a trend toward increased mortality. Caution must be taken to carefully consider the indications, risks, and benefits of corticosteroids when deciding on their use.

Citing Articles

In-hospital survival of critically ill COVID-19 patients treated with glucocorticoids: a multicenter real-world data study.

Angermair S, Hardenberg J, Rubarth K, Balzer F, Akbari N, Menk M Sci Rep. 2024; 14(1):12138.

PMID: 38802435 PMC: 11130266. DOI: 10.1038/s41598-024-62302-w.


Recent Data about the Use of Corticosteroids in Sepsis-Review of Recent Literature.

Lazar A Biomedicines. 2024; 12(5).

PMID: 38790946 PMC: 11118609. DOI: 10.3390/biomedicines12050984.


Glucocorticoid Use Audits.

Jacob J, Kalra S Indian J Endocrinol Metab. 2022; 26(3):195-197.

PMID: 36248047 PMC: 9555371. DOI: 10.4103/2230-8210.353248.


Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review.

Behal M, Barlow B, Mefford B, Thompson Bastin M, Donaldson J, Laine M Crit Care Explor. 2021; 3(7):e0492.

PMID: 34278319 PMC: 8280010. DOI: 10.1097/CCE.0000000000000492.


Steroid use in elderly critically ill COVID-19 patients.

Jung C, Wernly B, Fjolner J, Bruno R, Dudzinski D, Artigas A Eur Respir J. 2021; 58(4).

PMID: 34172464 PMC: 8246007. DOI: 10.1183/13993003.00979-2021.